<DOC>
	<DOC>NCT00640952</DOC>
	<brief_summary>The purpose of this study is to determine how many patients with Parkinson's disease have compulsive behaviors, and what types of behaviors they have. This study will also determine if acamprosate can be used to treat compulsive behaviors in Parkinson's disease patients.</brief_summary>
	<brief_title>Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>1. Idiopathic Parkinson's disease 2. Active dopaminergic therapy at stable dose for one month (levodopa or dopamine agonist) 3. Able and willing to complete Rating Scales 4. Presence of one or more compulsive behavior based on responses to Rating Scales (defined as &gt;5 on the SOGS; &gt;17 on the YBOCSSV and YBOCSCUV; &gt;1.7 on the SCS for women and &gt;2.1 on the SCS for men; &gt;15 on the YBOCSBE, &gt;5.5 on the CQ). 5. Written informed consent Inclusion criteria (controls): 1. No significant psychiatric disease 2. Able and willing to complete Rating Scales 3. Written informed consent 1. No anticipated need for adjustment of medications for Parkinson's disease 2. Current participation in another clinical study 3. History of unstable psychiatric disease (as determined by the Principal Investigator) 4. Women of childbearing age not using appropriate contraceptive methods (oral contraceptives, condoms, surgery)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Parkinson's disease</keyword>
	<keyword>impulse control behaviors</keyword>
	<keyword>dopa-dysregulation</keyword>
</DOC>